Lantheus Holdings, Inc. (NasdaqGM:LNTH) will look for M&A opportunities. During the company?s first quarter 2024 conference call, Brian Markison, Chief Executive Officer said that ?As we look to the future, we will utilize our balance sheet, strong cash flow and access to capital to execute a financially attractive business development and M&A opportunities that enhance our pipeline and capabilities in areas that we believe best align with our radiopharmaceutical expertise?.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.